Advisory · Rare Disease
Smaller patient populations, clearer endpoints, premium economics.
Ambrosia provides senior-led advisory for rare disease licensing, M&A, and strategic partnerships — backed by a proprietary database of 250 verified rare disease transactions.
Deal Landscape
What rare disease transactions actually look like.
Verified Transactions
250
Median Upfront
$110M
Key Structure Insight
Rare disease commands 28.7% upfront ratios — highest of any TA
Selected Work
Rare Disease·Rare disease program — global licensing engagement with milestone structure optimization
Related Insights
Research relevant to rare disease.
Stay Informed
Get new deal intelligence and transaction insights as we publish them.
No spam. Unsubscribe anytime.
Discuss your rare disease transaction.
We’ll meet you at peer level — anywhere in the world.